Key facts
- It has raised $15.5M across 1 recorded rounds; the latest was Early Stage VC ($15.5M) in Feb 2025.
- Notable investors include ARCH Venture Partners, Meltwind Advisory, ND Capital, OMX Ventures.
- Syndex Bio has filed 1 Form D with the SEC, most recently Mar 2025 ($15.5M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Syndex Bio
Funding rounds
1 roundsAbout Syndex Bio
Operator of a biotechnology research firm intended to discover a fuel tool for fuel biology. The company unlocks new insights in biology by building a powerful new platform that brings together molecular technologies, instrumentation, and AI to accelerate the understanding, diagnosis, and treatment of disease, enabling customers to gain a deeper understanding of biological processes and develop novel therapeutics.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2022
- Employees
- 10
- Website
- syndex.bio/
- Ownership
- Privately Held (backing)
Syndex Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syndex Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syndex Bio in its N-PORT filings yet. We sweep new filings monthly.